MRK - IPO Update: Nurix Therapeutics Prepares IPO Terms
Quick Take
Nurix Therapeutics (NRIX) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing drug candidates to treat various cancers.
NRIX has significant collaboration partners and a top tier investor syndicate, but the firm is still at an extremely early stage and the IPO is likely more suited to institutional investors rather than individual investors.
Company & Technology
San Francisco, California-based Nurix was founded to create a portfolio of chimeric targeting molecule-based drug candidates that serve